HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
Posted on: Sunday, 8 November 2009, 23:32 CST
SAN DIEGO, Nov. 9 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China. The agreement is another in a series of collaborations that HUYA has established with China's leading research and development institutions to enable and accelerate the global development and commercialization of novel biopharmaceutical product opportunities originating in China.
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new pre-clinical and clinical stage compounds. The agreement with Ocean University of China provides HUYA with rights of first review and negotiation relating to certain novel therapeutic and diagnostic product candidates owned or controlled by the University. In return, Ocean University of China gains access to HUYA's global network of pharmaceutical partners and its expertise in pre-clinical and clinical development.
"Ocean University is one of China's leading institutions, with considerable expertise in the field of marine pharmaceutical science," said Michael Newman, Ph.D., Executive Vice President of Oncology at HUYA Bioscience. "We look forward to collaborating with this prestigious university to bring novel biopharmaceutical products to the global marketplace."
"Ocean University is committed to strengthening its research programs in marine pharmaceutical science," said Qiangming Wu, Ph.D., Executive Dean, School of Medicine and Pharmacy, Ocean University of China. "We are pleased to partner with HUYA's expert team to achieve this objective."
ABOUT HUYA
HUYA is the leader in global pharmaceutical co-development with China. With six strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach to pharmaceutical co-development between the U.S. and China. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.
ABOUT OCEAN UNIVERSITY OF CHINA
Ocean University of China, located in Qingdao, is one of the top universities in China. It is considered a leader in research in the area of marine pharmaceutical science, and has received numerous awards for its work. The University has undertaken a large number of research papers and made great contributions to the construction of the marine-based economy of Shandong Province, including projects such as the seawater aquaculture. Ocean University has been ranked No. 8 in terms of the number of prizes won for science and technology advancement awarded by the Ministry of Education. For more information visit www.ouc.edu.cn/english.
CONTACT: USA: Bob Giargiari, MBA, EVP Finance & CFO HUYA Bioscience International, LLC (858) 798-8800 bgiargiari@huyabio.com China: Qing (Vicky) Xia, Scientific Research Manager HUYA Bioscience International, LLC 86 (21) 51323312 vxia@huyabio.com Media Contact: Juliet Travis (510) 452-3771 juliet@travispr.comSOURCE HUYA Bioscience International
Source: PR Newswire
Related Articles
- University Of Minnesota Researchers Develop Virtual Streams To Help Restore Real Ones
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
- Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
- Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
- Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer
- University of Arizona Researcher Develops New Tool for Rapid Assessment of Health Literacy Skills
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completes Submission of Tipifarnib NDA to FDA Continuous Marketing Application Pilot-1 Program
- University of Maryland Researchers Develop Anthrax Tracking Method
User Comments (0)

RSS Feeds